Question · asked by 1 review
RGD peptide matrix vs placebo: Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported
- Population
- individuals with sickle cell disease and a leg ulcer
- Intervention
- RGD peptide matrix
- Comparison
- placebo
- Outcome
- Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
RGD peptide matrix vs placebo Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and leg ulcer The review found no eligible studies for this question. Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.